Aleva attended the 17th Annual Conference of the German Society for Neuromodulation
Aleva attended the 17th Annual Conference of the German Society for Neuromodulation
Experts in functional neurosurgery and neurotechnology convened to discuss advances in precision stimulation and new therapeutic applications. Aleva joined the dialogue, presenting data and experience from its directional DBS system.
Experts in functional neurosurgery and neurotechnology convened to discuss advances in precision stimulation and new therapeutic applications. Aleva joined the dialogue, presenting data and experience from its directional DBS system.
October 19, 2022
October 19, 2022
Between the 4th and 5th of November, Aleva attended the 17th Annual Conference of the German Society for Neuromodulation.
The Annual Conference of the German Society for Neuromodulation (DGfN) is one of Europe’s key scientific meetings dedicated to advancing clinical practice and research in neurostimulation.
The event brings together neurologists, neurosurgeons, and researchers to exchange insights on emerging technologies, clinical results, and therapeutic innovations across deep brain, spinal, and peripheral nerve stimulation.
This year’s programme featured sessions on new indications for DBS, long-term outcomes in movement disorders, and the role of neuromodulation in psychiatric and pain conditions — providing a platform for collaboration between clinicians, academia, and industry.
Between the 4th and 5th of November, Aleva attended the 17th Annual Conference of the German Society for Neuromodulation.
The Annual Conference of the German Society for Neuromodulation (DGfN) is one of Europe’s key scientific meetings dedicated to advancing clinical practice and research in neurostimulation.
The event brings together neurologists, neurosurgeons, and researchers to exchange insights on emerging technologies, clinical results, and therapeutic innovations across deep brain, spinal, and peripheral nerve stimulation.
This year’s programme featured sessions on new indications for DBS, long-term outcomes in movement disorders, and the role of neuromodulation in psychiatric and pain conditions — providing a platform for collaboration between clinicians, academia, and industry.
— By Aleva Neurotherapeutics
— By Aleva Neurotherapeutics
More from the Journal
More from the Journal
Read more on Aleva’s technology milestones, partnerships, and clinical developments.
Read more on Aleva’s technology milestones, partnerships, and clinical developments.
Beyond techniques or tools, therapy works best when it feels safe, real, and human.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes.
Explore the science, validation, and opportunities driving Aleva forward.
RECOGNITION
Recognition & Collaborations
Aleva’s progress has been supported and acknowledged by leading clinical institutions, innovation agencies, research programmes and long-term investment partners.
